Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

AstraZeneca to Continue Roxadustat Sales in China; Returns Other Rights

publication date: Feb 28, 2024

AstraZeneca has returned most of the global rights for Roxadustat to FibroGen, though it will retain the rights for China and South Korean, where the drug is approved. Roxadustat is an oral HIF-PH inhibitor that promotes red blood cell production. It is approved in China to treat patients with anemia from renal failure, whether they are on dialysis or not. The companies were not able to satisfy US regulators that Roxadustat was effective. In 2023, Roxadustat generated $281 million in China revenues, which should climb over $300 million this year after it is approved to treat anemia from MDS. More details...

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital